Ultima Genomics
Investors
Venture capital firms, private equity investors, and strategic partners
| Investor | Type |
|---|---|
D1 Capital Partners | Hedge Fund |
Common Investor Types
- •Venture Capital Firms: Early-stage and growth equity investors
- •Private Equity: Later-stage institutional investors
- •Strategic Investors: Corporations in related industries
- •Angel Investors: High-net-worth individuals
- •Family Offices: Private wealth management firms
What Investors Provide
- ✓Capital for growth and expansion
- ✓Strategic guidance and expertise
- ✓Industry connections and partnerships
- ✓Market validation and credibility
- ✓Board representation and governance
Who Invested in Ultima Genomics?
Ultima Genomics has attracted investment from 1+ venture capital firms, private equity investors, and strategic partners across 1 funding rounds.
Why Do Investors Fund Ultima Genomics?
Investors are attracted to Ultima Genomics due to the company's strong market position, growth potential, and proven business model in the Other Healthcare Technology Systems industry.
Types of Ultima Genomics Investors
Ultima Genomics investors typically include a mix of venture capital firms providing growth capital, private equity firms for later-stage funding, strategic corporate investors from related industries, and high-net-worth angel investors. Each investor type brings unique value beyond capital, including industry expertise, strategic partnerships, and operational guidance.
Investor FAQs
How many investors does Ultima Genomics have?
Ultima Genomics has had 1+ investors participate across its funding rounds. This includes venture capital firms, private equity investors, strategic partners, and angel investors.
Who are the lead investors in Ultima Genomics?
Lead investors typically invest the largest amounts and often take board seats. For detailed information about Ultima Genomics's lead investors and cap table structure, please contact our team.
Can I become an investor in Ultima Genomics?
Accredited investors can purchase Ultima Genomics shares on the secondary market through Premier Alternatives. This provides an opportunity to invest in the company before a potential IPO or acquisition event.